We expect that ANAVEX’s lead drug candidate ANAVEX 2-73 -targeting Alzheimer’s disease- will enter Phase I/IIa clinical trials by September. In parallel, Anavex is preparing the IND file for another CNS drug targeting epilepsy and one IND file for an oncology drug that could directly enter Phase II clinical trial.

Other early-stage preclinical research (see diagram) involves drug candidates that target diseases like stroke, depression, neuropathic pain and various types of cancer.

The company has over 30 novel drug candidates and is open to discussions with industrial partners.